Department of Clinical Laboratory, Wu'an First People's Hospital, Handan, China.
Department of Clinical Laboratory, Peking University People's Hospital, Beijing, China.
Biomed Res Int. 2020 Sep 10;2020:2810150. doi: 10.1155/2020/2810150. eCollection 2020.
To assess the expression and clinical value of miR-19 in gastrointestinal malignancy. . Embase, Web of Science, PubMed, and other databases were retrieved to screen out relevant studies until December 31, 2019. . Gastrointestinal cancer patients with the description of miR-19 expression, as well as the correlation between miR-19 and clinicopathological characteristics or prognosis. . Pooled odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) was obtained to determine miR-19 expression in gastrointestinal malignancy and the association between miR-19 and patients' clinical characteristics and survival.
Thirty-seven studies were included in this study. miR-19 levels in gastrointestinal malignancy, especially in hepatocellular (OR = 4.88, 95% CI = 2.38-9.99), colorectal (OR = 4.81, 95% CI = 2.38-9.72), and pancreatic (OR = 5.12, 95% CI = 2.43-10.78) cancers, were significantly overexpressed, and miR-19 was tightly related to some clinicopathological characteristics, such as lymph node metastasis (OR = 1.74, 95% CI = 1.05-2.86). Although gastrointestinal cancer patients with low and high miR-19 expression had comparable OS (overall survival) and DFS (disease-free survival), subgroup analyses showed that patients with high miR-19 presented better DFS than those with low miR-19 in liver cancer (HR = 0.46, 95% CI = 0.30-0.71).
miR-19 might be a potential progression and prognostic biomarker for gastrointestinal malignancy.
评估 miR-19 在胃肠恶性肿瘤中的表达及临床价值。
计算机检索 Embase、Web of Science、PubMed 等数据库，检索时限均从建库至 2019 年 12 月 31 日，收集 miR-19 表达与胃肠恶性肿瘤相关的研究。
①研究类型为病例对照研究或队列研究；②研究对象为经病理组织学或细胞学检查证实为胃肠恶性肿瘤的患者；③研究中阐述了 miR-19 的表达情况，且分析了 miR-19 与临床病理特征或预后的关系。
①重复发表或数据重复利用的文献；②综述、会议摘要、病例报道等类型的文献。
由 2 位研究者独立提取资料并交叉核对，提取内容包括纳入研究的基本信息、miR-19 的表达情况、研究对象的临床病理特征及生存预后情况等。
采用纽卡斯尔-渥太华量表（NOS）对纳入文献进行质量评价。
采用 Review Manager 5.3 软件进行荟萃分析。计数资料采用比值比（OR）及其 95%可信区间（CI）表示；计量资料采用均数差（MD）及其 95%CI 表示。采用 χ²检验进行异质性检验，当 P<0.05 或 I²>50%时，采用随机效应模型进行分析；反之，则采用固定效应模型进行分析。采用敏感性分析和漏斗图评估发表偏倚。
共纳入 37 项研究，包含 7721 例胃肠恶性肿瘤患者和 7154 例对照者。荟萃分析结果显示，与癌旁组织或正常组织相比，miR-19 在胃癌（OR=4.88，95%CI=2.389.99）、结直肠癌（OR=4.81，95%CI=2.389.72）和胰腺癌（OR=5.12，95%CI=2.4310.78）中呈高表达，且与肿瘤的淋巴结转移（OR=1.74，95%CI=1.052.86）等临床病理特征密切相关。尽管 miR-19 高表达组与低表达组患者的总生存（OS）和无病生存（DFS）差异无统计学意义，但亚组分析显示，在肝癌中 miR-19 高表达组的 DFS 优于 miR-19 低表达组（HR=0.46，95%CI=0.30~0.71）。
miR-19 可能是一种有潜力的胃肠恶性肿瘤进展和预后生物标志物。
